Prevalence of Scabies and Impetigo 3 Years After Mass Drug Administration With Ivermectin and Azithromycin.
impetigo
ivermectin
mass drug administration
neglected tropical diseases
scabies
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
10 04 2020
10 04 2020
Historique:
received:
08
04
2019
accepted:
24
05
2019
pubmed:
28
5
2019
medline:
7
1
2021
entrez:
28
5
2019
Statut:
ppublish
Résumé
Ivermectin-based mass drug administration has emerged as a promising strategy for the control of scabies and impetigo in settings where the diseases are endemic. Current follow-up data are limited to 12 months for the majority of studies. Longer-term data are vital to inform the sustainability of interventions. We conducted a prevalence survey for scabies and impetigo in 10 villages in Choiseul Province of the Solomon Islands 36 months after a single round of ivermectin and azithromycin mass drug coadministration. In the primary analysis, we compared the prevalence of scabies and impetigo at 36 months to the prevalence at baseline. At 36 months, the prevalence of scabies was 4.7% (95% confidence interval [CI], 3.6-6.1), which was significantly lower than at baseline (18.7%; relative reduction, 74.9%; 95% CI, 61.5%-87.7%; P < .001). The prevalence of impetigo was 9.6% (95% CI, 8.1%-11.4%), significantly lower than at baseline (24.7%; relative reduction, 61.3%; 95% CI, 38.7%-100%; P < .001). The highest prevalence of scabies was among children aged <5 years (12.5%; adjusted odds ratio, 33.2; 95% CI, 6.6-603.2), and the highest prevalence of impetigo was among children aged 5-9 years (16.4%; adjusted odds ratio, 8.1; 95% CI, 3.6-21.8). There was a sustained impact of a single round of ivermectin and azithromycin mass drug coadministration on the prevalence of scabies and impetigo 3 years after the intervention. Our data provide further support to adopt this intervention as a central component of global scabies control efforts. Australian and New Zealand Trials Registry (ACTRN12615001199505).
Sections du résumé
BACKGROUND
Ivermectin-based mass drug administration has emerged as a promising strategy for the control of scabies and impetigo in settings where the diseases are endemic. Current follow-up data are limited to 12 months for the majority of studies. Longer-term data are vital to inform the sustainability of interventions.
METHODS
We conducted a prevalence survey for scabies and impetigo in 10 villages in Choiseul Province of the Solomon Islands 36 months after a single round of ivermectin and azithromycin mass drug coadministration. In the primary analysis, we compared the prevalence of scabies and impetigo at 36 months to the prevalence at baseline.
RESULTS
At 36 months, the prevalence of scabies was 4.7% (95% confidence interval [CI], 3.6-6.1), which was significantly lower than at baseline (18.7%; relative reduction, 74.9%; 95% CI, 61.5%-87.7%; P < .001). The prevalence of impetigo was 9.6% (95% CI, 8.1%-11.4%), significantly lower than at baseline (24.7%; relative reduction, 61.3%; 95% CI, 38.7%-100%; P < .001). The highest prevalence of scabies was among children aged <5 years (12.5%; adjusted odds ratio, 33.2; 95% CI, 6.6-603.2), and the highest prevalence of impetigo was among children aged 5-9 years (16.4%; adjusted odds ratio, 8.1; 95% CI, 3.6-21.8).
CONCLUSIONS
There was a sustained impact of a single round of ivermectin and azithromycin mass drug coadministration on the prevalence of scabies and impetigo 3 years after the intervention. Our data provide further support to adopt this intervention as a central component of global scabies control efforts.
CLINICAL TRIALS REGISTRATION
Australian and New Zealand Trials Registry (ACTRN12615001199505).
Identifiants
pubmed: 31131410
pii: 5498744
doi: 10.1093/cid/ciz444
pmc: PMC7145994
doi:
Substances chimiques
Ivermectin
70288-86-7
Azithromycin
83905-01-5
Banques de données
ANZCTR
['ACTRN12615001199505']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1591-1595Subventions
Organisme : Wellcome Trust
ID : 102807
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 098521
Pays : United Kingdom
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Lancet. 1991 Apr 27;337(8748):1016-8
pubmed: 1673175
Clin Infect Dis. 2019 Mar 5;68(6):927-933
pubmed: 29985978
Lancet Infect Dis. 2015 Aug;15(8):960-7
pubmed: 26088526
PLoS Negl Trop Dis. 2015 Mar 04;9(3):e0003452
pubmed: 25738499
BMJ. 2003 Jan 25;326(7382):219
pubmed: 12543843
PLoS Negl Trop Dis. 2015 Oct 30;9(10):e0004151
pubmed: 26516764
Trop Doct. 2001 Jan;31(1):15-8
pubmed: 11205591
Bull World Health Organ. 2009 Mar;87(3):173-9
pubmed: 19377712
J Am Acad Dermatol. 1983 Oct;9(4):550-4
pubmed: 6195201
Bull World Health Organ. 2005 Jan;83(1):34-42
pubmed: 15682247
Bull World Health Organ. 2006 Aug;84(8):613-9
pubmed: 16917648
Lancet. 2006 May 27;367(9524):1767-74
pubmed: 16731272
Lancet Glob Health. 2018 Oct;6(10):e1132-e1138
pubmed: 30223985
J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):236-40
pubmed: 10642678
PLoS Negl Trop Dis. 2016 Jun 27;10(6):e0004803
pubmed: 27348119
PLoS Negl Trop Dis. 2015 Dec 01;9(12):e0004246
pubmed: 26624616
PLoS Negl Trop Dis. 2009 May 26;3(5):e444
pubmed: 19478832
Bull World Health Organ. 2009 Oct;87(10):A; author reply B
pubmed: 19876530
Trans R Soc Trop Med Hyg. 2005 Jan;99(1):39-47
pubmed: 15550260
Lancet Infect Dis. 2019 May;19(5):510-518
pubmed: 30956111
N Engl J Med. 2015 Dec 10;373(24):2305-13
pubmed: 26650152
Acta Trop. 2000 Feb 25;75(1):127-30
pubmed: 10708015